Chargement en cours...
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
INTRODUCTION: The fluoropyrimidines (FP) (5-Fluorouracil, capecitabine, and tegafur) are commonly used anti-cancer drugs, but lead to moderate to severe toxicity in about 10–40% of patients. DPD testing [either the enzyme activity of dihydropyrimidine dehydrogenase (DPD) or the DPYD genotype] identi...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6997151/ https://ncbi.nlm.nih.gov/pubmed/32047438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01609 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|